Distinguished Professor, Translational Genomics Research Institute (TGen)
Distinguished Professor, Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California
Virginia G. Piper Distinguished Chair for Innovative Cancer Research, HonorHealth Clinical Research Institute
Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Family Cancer Institute
Chief Scientific Officer for US Oncology Research
Professor of Medicine
University of Arizona
Mayo Clinic, Scottsdale, Arizona
For his groundbreaking accomplishments as a dedicated and inspirational educator, for his sustained scientific innovation that has accelerated advances in cancer science and medicine, and for his extraordinary contributions to the education and training of thousands of clinical cancer investigators.
An internationally renowned cancer researcher, Von Hoff has contributed to the discovery and development of many approved anticancer therapeutics that are used routinely in the treatment of numerous types of cancer. These therapeutics include, but are not limited to, dexrazoxane, docetaxel, fludarabine, gemcitabine, irinotecan, mitoxantrone, nab-paclitaxel, paclitaxel, topotecan, vismodegib, pexidartinib, and nanoliposomal irinotecan. Notably, his work involving gemcitabine and nab-paclitaxel combination therapy in pancreatic cancer patients was one of the first to demonstrate improved response rates, progression-free survival, and overall survival in patients with metastatic pancreatic cancer.
In addition to his scientific leadership, Von Hoff has long been a champion and mentor of early-career and early-stage investigators and is dedicated to supporting the professional development of the cancer research workforce. Importantly, Von Hoff is revered for conceptualizing the AACR/ASCO Methods in Clinical Cancer Research Workshop and for establishing and guiding the development of the course. As such, the course has become the premier workshop dedicated to educating clinical fellows and junior faculty clinical researchers in oncology specialties in the principles of effective clinical trial designs and therapeutic interventions for the treatment of cancer. Since its inception in 1996, the workshop has trained more than 2,400 investigators to execute optimally designed clinical research studies.. The concept of this workshop has also been globally adapted to similar workshops in Europe as well as Australia, which has drawn attendance from individuals from India, New Zealand, Pakistan, and many other countries within Southeast Asia. Collectively, more than 4,400 young clinical investigators have been trained through these workshops. Read the press release.